GEXVal CEO Invited to Present at Australian Embassy Clinical Development Forum

株式會社GEXVal
June 10, 2025

GEXVal CEO Invited to Present at Australian Embassy Forum on Fast-Tracking Clinical Development

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Dr. Juran Kato has been invited to present and serve as moderator at "Fast-Tracking Clinical Development Through Australia: A Strategic Opportunity for Japanese Biopharma Companies," hosted by the Australian and New Zealand Chamber of Commerce in Japan (ANZCCJ) ¹⁾and supported by the Australian Embassy in Japan.

Juran Kato, PhD, President and CEO of GEXVal, stated: "We are deeply honored to have been invited as a representative Japanese company to share our experience in Australia's clinical development ecosystem. Through our Australian subsidiary, we completed not only Phase I trials but also confirmed target engagement—a value-creating approach that enabled us to advance our drug development program efficiently and strategically. Cross-border collaboration is essential in pharmaceutical development, and I look forward to sharing these learnings to strengthen the partnership between our two nations in biotechnology and contribute to the Asia-Pacific drug discovery ecosystem. As moderator, I also look forward to learning from stakeholder insights and deepening our understanding of practical challenges and considerations that require careful preparation when undertaking clinical development in Australia."

■ Event Details ■
This event, to be held at the Australian Embassy in Mita, Tokyo, Japan introduces Japanese biopharma companies to strategic opportunities for accelerated clinical development in Australia. Alongside leading Australian clinical trial service providers, the forum will feature discussions on how efficient processes, regulatory advantages, and deep therapeutic expertise are accelerating drug development through real-world case studies and practical insights.

GEXVal has completed Phase I and Proof of Mechanism (PoM)²⁾ trials through our Australian subsidiary, GEXVal AU Pty Ltd, pioneering high-quality clinical development in Australia among Japanese clinical-stage biopharma companies. This invitation—the only one extended to a Japanese company—reflects international recognition of our track record and expertise. Details of our clinical trial are available in the Australian New Zealand Clinical Trials Registry (ANZCTR, Registration number: ACTRN12622000743763).
https://www.anzctr.org.au/TrialSearch.aspx

1) About ANZCCJ
The Australian and New Zealand Chamber of Commerce in Japan (ANZCCJ) is a non-profit organization established in 1972 to play a meaningful role in developing business relationships between Australia, New Zealand, and Japan. With over 500 members, ANZCCJ comprises companies and international members engaged in bilateral economic relationships between these nations.
Details: https://www.anzccj.jp

2) About PoM (Proof of Mechanism)
A study that confirms target engagement—scientifically demonstrating that a drug interacts with its intended molecular target. PoM trials measure and verify molecular-level or systemic physiological indicators resulting from the drug's pharmacological action.

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com